Clinical investigation finds metabolic disorders drive fatty liver disease in HIV-monoinfected individuals, highlighting the need for inclusive NASH trials.
NAFLD is frequently observed in HIV-monoinfected patients, and NASH is a common cause of unexplained abnormal liver function in patients selected for liver biopsy. Metabolic disorders are key risk factors independently of HIV parameters. Future trials on pharmacological interventions in NASH with fibrosis should include patients with HIV.
No takes yet. Share an insight, caveat, or question.
Maurice et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: